GMD Classification Under TR-003: Rules, Four Classes and Consequences

1. Key takeaways

General medical devices in Hong Kong, China fall into 4 classes, I, II, III and IV, with the rules set out in technical reference document TR-003, Classification of General Medical Devices. The methodology derives from the harmonisation documents of the Global Harmonization Task Force (GHTF), which was dissolved in 2011 and succeeded by the International Medical Device Regulators Forum (IMDRF). Classification decides three things: whether a listing can be applied for, since Class I cannot; whether the device falls within the mandatory procurement scope, since only Class II and above counts as an applicable medical device; and the depth of documentation, which rises with class.

Those three consequences are usually discussed separately inside a company, by regulatory affairs, by sales and by the quality function. They are in fact one decision made once. A class assigned at the start of a project fixes the evidence budget, the launch date and the tender position, and it is much harder to change after a submission than before it.

The GRZAN view. Classification disputes rarely concern the rule. They concern the intended use sentence, which is why the claim and the class have to be written together.

2. Legal basis

A rule set rather than a catalogue. TR-003 classifies by answering structured questions about the device: whether it is invasive, by what route, for how long, whether it supplies energy, whether it acts on the central circulatory system, and whether it is absorbable. GN-00 supplies the definitions and abbreviations on which those questions depend, in a Chinese version updated on 2 October 2025. GN-02 sets the documentation requirements for listing Class II, III and IV devices. The MDACS scheme page illustrates classification with examples, and the joint response of the Health Bureau and the Department of Health, press release P2024011500706 of 15 January 2024, records in a note that the GHTF was established in 1992, dissolved in 2011, and succeeded by the IMDRF.

The official tool produces a record. MDD publishes a general medical device classification programme online. Its determination can be printed and filed, and the resulting record is the document most often requested by purchasers alongside the listing itself.

3. Expert insights

TR-003 is a rule set, not a product list. Classification does not proceed by looking up a catalogue entry. It proceeds by answering questions: is the device invasive, by which route, for how long, does it supply energy, does it act on the central circulatory system, is it absorbable. Because the answers depend on the wording of the intended use, the same family of products can land in different classes when the claim changes. That is the main source of classification disputes, and it explains why a competitor product carrying the same class is weak evidence for your own.

GHTF lineage is a practical dividend, within limits. Since the methodology runs in the same line as the GHTF and IMDRF documents, existing classifications from the Chinese mainland, the European Union and the United States usually carry real reference value. They cannot simply be transplanted. Hong Kong, China applies the rules in TR-003 and the output of the official online tool, so a foreign classification functions as supporting material that explains a conclusion, not as the conclusion itself. Where the two differ, the difference has to be explained rather than ignored.

The tool output carries evidential weight. In tenders and in disputes, purchasers generally accept a combination of the official tool output and a citation of the relevant TR-003 provision as the basis for classification, a practical estimate rather than a documented rule. That combination is stronger than a narrative explanation, because it can be reproduced by the reader.

Classification is bound tightly to the listing scope. Class II and above enter the listing channel and are also what the Phase C procurement rules call applicable medical devices. A class assigned too low therefore removes listing eligibility and tender eligibility in a single step, and the loss is not recoverable within the same procurement cycle.

4. Practical recommendations

• Classify by rule, not by precedent. Record the determination dimension by dimension against TR-003, rather than relying on the class given to a similar product last time.
• Align the intended use with the class. The intended use is the central input to classification, so the wording in the instructions, label and promotional material must match what was submitted.
• Archive foreign classifications as support. Keep the NMPA catalogue determination and the EU MDR class on file to explain the reasoning, clearly labelled as supporting rather than governing.
• Ask MDD before drafting for novel products. Where TR-003 does not clearly cover a new technology, query MDD in writing before committing to document preparation.
• Re-run the determination on change. Any change to claim, materials, contact duration or energy delivery is a trigger to reassess, not a minor document update.

5. Verification checklist

• □ Classification determination completed against each TR-003 dimension and recorded.
• □ Official general medical device classification programme used and output retained.
• □ Intended use wording consistent across instructions, label and promotional material.
• □ Foreign classification conclusions archived as supporting evidence.
• □ Class confirmed as II, III or IV, that is, within the listing scope.
• □ Open classification questions put to MDD in writing, with the reply retained.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages Medical Device Administrative Control System (MDACS) listings, coordinates import licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com